AKT2 and chronic myelogenous leukemia, BCR-ABL1 positive: Through identification, we screened 11 CML HSC‐treated biomarkers and candidate targets, including KIT, MCL1, FOS, BRCA1, FLT3, CD44, AKT2, CHEK1, BCL6, and BCL2L1, and CREB1. KIT is a type III receptor tyrosine kinase that promotes cell survival and cells by activating downstream signaling pathways, proliferation and inhibition of apoptosis.